Novartis marks a new era for migraine patients with the EU approval of Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention
- Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and tolerability were similar to placebo[1]-[3]
- Migraine is the third leading cause of disability in people under 50, leading to severe disruption to the personal and professional lives of millions of sufferers; it is estimated to cost up to ?27 billion per year in Europe alone[4],[5]
- Aimovig is the first and only approved migraine prevention treatment designed specifically to block the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine ?????
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Angela Fiorin Novartis Global Pharma Communications +41 61 324 8631 (direct) +41 79 752 6955 (mobile) angela.fiorin@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 212 830 2448 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 212 830 2417 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |